PAMELA POURCIAU: Open Payments
NPI 1053672691 · LA PLACE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,717 in 68 payments from 23 companies in 2025. Trend: 2023 $1,197 · 2024 $1,283 · 2025 $1,717
Food & beverage: $1,717
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 7 | $270 |
| Novartis Pharmaceuticals Corporation | 12 | $198 |
| ABBVIE INC. | 10 | $155 |
| ARGENX US, INC. | 6 | $147 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Alexion Pharmaceuticals, Inc. | 1 | $126 |
| Edwards Lifesciences Corporation | 1 | $125 |
| Lilly USA, LLC | 6 | $107 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: KESIMPTA, Fintepla, VYVGART HYTRULO, REZDIFFRA, ULTOMIRIS, AMYVID, BOTOX, Briviact.
Industry payments across LA — which companies pay providers there.
